These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 37478665)

  • 1. Current application status and structure-activity relationship of selective and non-selective JAK inhibitors in diseases.
    Li T; Yang X; Zhu J; Liu Y; Jin X; Chen G; Ye L
    Int Immunopharmacol; 2023 Sep; 122():110660. PubMed ID: 37478665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways.
    Johnson B; Cheng L; Koenitzer J; Catlett IM; Schafer P
    Front Immunol; 2024; 15():1437512. PubMed ID: 39403378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
    Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
    J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
    Hammitzsch A; Lorenz G; Moog P
    Front Immunol; 2020; 11():591176. PubMed ID: 33193430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
    Roskoski R
    Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.
    Shen P; Wang Y; Jia X; Xu P; Qin L; Feng X; Li Z; Qiu Z
    Eur J Med Chem; 2022 Sep; 239():114551. PubMed ID: 35749986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
    He X; Chen X; Zhang H; Xie T; Ye XY
    Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.
    Wang L; Hu Y; Song B; Xiong Y; Wang J; Chen D
    Inflamm Res; 2021 Jul; 70(7):753-764. PubMed ID: 34212215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.
    Kim HO
    Arch Pharm Res; 2020 Nov; 43(11):1173-1186. PubMed ID: 33161563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.
    Meyer SC; Levine RL
    Clin Cancer Res; 2014 Apr; 20(8):2051-9. PubMed ID: 24583800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dissection of Janus kinases as drug targets for inflammatory diseases.
    Kwon S
    Front Immunol; 2022; 13():1075192. PubMed ID: 36569926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
    Alunno A; Padjen I; Fanouriakis A; Boumpas DT
    Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
    Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
    Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
    Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
    Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
    Roskoski R
    Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinase inhibitors in autoimmune bullous diseases.
    Huang D; Zhang Y; Kong L; Lu J; Shi Y
    Front Immunol; 2023; 14():1220887. PubMed ID: 37492565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
    Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
    Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis.
    Singh S; Singh S
    Int Immunopharmacol; 2020 Sep; 86():106731. PubMed ID: 32590315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.